New pill shows promise for kidney disease in Mid-Stage trial
NCT ID NCT05016323
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine, a sign of kidney damage, and find the best dose. Participants took either the drug or a placebo for a set period, and researchers measured changes in kidney function and protein levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Immune cell therapy takes on kidney disease
- Steroids for kidney disease: do they prevent failure Long-Term?